Sierra Summit Advisors’s Immunic IMUX Stock Holding History

Sierra Summit Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-32,483	Closed	-$487K	–	184
2023 Q4	$487K	Buy	+32,483	New	+$398K	0.14%	87

Other funds holding IMUX

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Sierra Summit Advisors's IMUX Position: Q1 2024 in Review

Sierra Summit Advisors sold out of Immunic (IMUX) in Q1 2024, closing a stake of 32,483 shares — an estimated $487K sold.

Sierra Summit Advisors first reported a position in IMUX in Q4 2023 and held it in 1 quarter. The position peaked at $487K in Q4 2023. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2024.

Sierra Summit Advisors reported no remaining Immunic position as of Q1 2024 after selling out during the quarter.
Sierra Summit Advisors sold 32,483 Immunic shares in Q1 2024, an estimated $487K.
Sierra Summit Advisors first reported a position in Immunic in Q4 2023 and held it in 1 quarter.
Sierra Summit Advisors's Immunic position peaked at $487K in Q4 2023.
59 funds tracked by Wall St. Rank held Immunic as of Q1 2024.

Based on Sierra Summit Advisors's 13F filing for Q1 2024, filed 9 May 2024.